Momentum and Value Watchlist: PERI, AMRS, and MEIP
The market has been running red hot, with stocks across every segment and sector being scooped up and launched higher. But that doesn’t mean it’s too late to scope out new opportunities. With increasingly positive sentiment moving into the stock market, investors make a mistake by looking for the party to end while the music is still playing.
And here are three interesting small caps that may be ready to dance.
Perion Network Ltd. (PERI)
According to the company’s press materials, Perion is a global technology company that delivers high-quality advertising solutions to brands and publishers. Perion is committed to providing outstanding execution, from high-impact ad formats to native ads, branded search and a unified social and mobile programmatic platform.
The stock has been ripping higher as investors start to price in improving credit resources. To validate that point, the company just that Standard & Poor’s Maalot Ratings Services has reaffirmed Perion’s corporate credit rating of ilA-, with a stable outlook.
Mr. Yacov Kaufman, Perion’s Chief Financial Officer and interim Chief Executive Officer, commented, “We are very pleased with the reaffirmation of our Credit Rating, which is a testament to our strong and steady cashflow.”
Shares of the stock broke out higher on the news, reinforcing an extremely strong trend.
MEI Pharma, Inc. (MEIP)
MEIP is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat is being developed in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy and high-risk MDS.
The Company’s clinical-stage pipeline also includes ME-401, an oral PI3K delta inhibitor currently in a Phase Ib study in patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin’s lymphoma, and ME-344, a mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer.
Shares of the stock have begun to break out of their recent range with a vengeance in recent trade highlighting a spirit of strong momentum that may spell further opportunity.
s stocks Amyris, Inc. (AMRS)
AMRS styles itself as “the industrial bioscience company”. The company recently provided an update on certain aspects of its business and financial results for 2016.
“We are pleased to have achieved a record year of revenue growth, and of having completed all of the 2016 strategic milestones we set out to, and we continue to make good progress on our debt structure by having resolved our near-term debt maturity issues in pushing out approximately $44 million in debt as announced just before year end,” said John Melo, Amyris President & CEO. “Also, we are meeting our expectations in securing collaborations that will result in future product sales and this is accelerating our growth rate.”
Shares have dropped back down to interesting levels and now hover around potentially significant support. There are two key themes that mark out opportunities: momentum and value. AMRS may be the latter form. The stock presents some interesting dynamics, both technical and fundamental, and may be worth a further look.